Boston Scientific Corporation (NYSE: BSX) today announced 30-day safety data from its TAXUS IV clinical trial. The trial is studying 1,326 patients at 72 sites in the United States, assessing the safety and efficacy of a slow-release formulation paclitaxel-eluting stent.
The Company made the announcement at the annual Transcatheter Cardiovascular Therapeutics symposium in Washington, D.C. The randomized, double-blind, pivotal trial is designed to assess the safety and efficacy of a paclitaxel-eluting coronary stent in reducing restenosis in de novo lesions 10 – 28 mm in length and 2.5 – 3.75 mm in diameter.
The study is using the Express stent, Boston Scientific’s internally developed stent approved earlier this month by the U.S. Food and Drug Administration and granted CE Mark last year.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!